JCXH-213 / Immorna - LARVOL DELTA

A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia (clinicaltrials.gov) - P1 | N=4 | Not yet recruiting | Sponsor: The General Hospital of Western Theater Command

New P1 trial • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

JCXH-213-001: One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL (clinicaltrials.gov) - P=N/A | N=8 | Recruiting | Sponsor: Beijing GoBroad Hospital | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Feb 2026 ➔ Aug 2026

Enrollment open • Trial initiation date • Trial primary completion date • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology